We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights NIKE, Stryker and TJX
Read MoreHide Full Article
For Immediate Release
Chicago, IL – June 27, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NIKE, Inc. (NKE - Free Report) , Stryker Corp. (SYK - Free Report) and The TJX Companies, Inc. (TJX - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for NIKE, Stryker and TJX
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NIKE, Inc., Stryker Corp. and The TJX Companies, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of NIKE have underperformed the Zacks Shoes and Retail Apparel industry over the year-to-date period (-14.1% vs. -9.2%). The company is witnessing persistence of inflationary pressures. Elevated demand creation expenses led to higher SG&A expenses.
Nevertheless, NIKE is benefiting from continued progress on Consumer Direct Acceleration strategy, compelling product innovation and digital leadership. This aided retail sales across Nike Direct business in third-quarter fiscal 2024.
The digital unit benefited from robust consumer trends, including momentum in the NIKE mobile app led by improved traffic and higher member buying frequency. It posted top and bottom-line growth in the quarter. Looking ahead, the company expects strong gross margin execution and disciplined cost management.
Stryker’s shares have outperformed the Zacks Medical - Products industry over the past year (+13.1% vs. -2.0%). The company exited first-quarter 2024 on a strong note with better-than-expected earnings and revenues. The company witnessed strong performance across its segments in the United States. Strong International sales also buoy optimism.
The momentum is expected to continue in 2024 on the back of ongoing procedural recovery and a strong order book for capital equipment. Stryker’s prospects in 2024 seem promising on the back of strong customer demand for its existing products as well as new launches. The company’s guidance for earnings and revenues appears encouraging. A solid solvency position is a plus.
However, inflationary pressure and supply-chain challenges continue to plague Stryker. Stiff competition in the MedTech space remains a woe. Contraction in both gross and operating margin is a woe.
Shares ofTJX have outperformed the Zacks Retail - Discount Stores industry over the past six months (+19.3% vs. +17.7%). The company’s off-price business model, strategic store locations, impressive brands and supply-chain management are working well. TJX has been benefiting from robust growth in its Marmaxx, HomeGoods and International segments, a trend that continued in first-quarter fiscal 2025.
Comparable store sales saw a rise, indicating sustained momentum. The company anticipates a 2-3% rise in comparable store sales for fiscal 2025. With a solid pre-tax margin, the company is poised for steady profitability, supported by improved merchandise margins. Also, management is on track with expansion efforts.
However, the company has been grappling with increased costs for a while now. Rising selling, general and administrative (SG&A) expenses are a concern for the company. Unfavorable foreign currency fluctuations might also act as a deterrent.
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights NIKE, Stryker and TJX
For Immediate Release
Chicago, IL – June 27, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: NIKE, Inc. (NKE - Free Report) , Stryker Corp. (SYK - Free Report) and The TJX Companies, Inc. (TJX - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for NIKE, Stryker and TJX
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including NIKE, Inc., Stryker Corp. and The TJX Companies, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of NIKE have underperformed the Zacks Shoes and Retail Apparel industry over the year-to-date period (-14.1% vs. -9.2%). The company is witnessing persistence of inflationary pressures. Elevated demand creation expenses led to higher SG&A expenses.
Nevertheless, NIKE is benefiting from continued progress on Consumer Direct Acceleration strategy, compelling product innovation and digital leadership. This aided retail sales across Nike Direct business in third-quarter fiscal 2024.
The digital unit benefited from robust consumer trends, including momentum in the NIKE mobile app led by improved traffic and higher member buying frequency. It posted top and bottom-line growth in the quarter. Looking ahead, the company expects strong gross margin execution and disciplined cost management.
(You can read the full research report on Nike here >>>)
Stryker’s shares have outperformed the Zacks Medical - Products industry over the past year (+13.1% vs. -2.0%). The company exited first-quarter 2024 on a strong note with better-than-expected earnings and revenues. The company witnessed strong performance across its segments in the United States. Strong International sales also buoy optimism.
The momentum is expected to continue in 2024 on the back of ongoing procedural recovery and a strong order book for capital equipment. Stryker’s prospects in 2024 seem promising on the back of strong customer demand for its existing products as well as new launches. The company’s guidance for earnings and revenues appears encouraging. A solid solvency position is a plus.
However, inflationary pressure and supply-chain challenges continue to plague Stryker. Stiff competition in the MedTech space remains a woe. Contraction in both gross and operating margin is a woe.
(You can read the full research report on Stryker here >>>)
Shares ofTJX have outperformed the Zacks Retail - Discount Stores industry over the past six months (+19.3% vs. +17.7%). The company’s off-price business model, strategic store locations, impressive brands and supply-chain management are working well. TJX has been benefiting from robust growth in its Marmaxx, HomeGoods and International segments, a trend that continued in first-quarter fiscal 2025.
Comparable store sales saw a rise, indicating sustained momentum. The company anticipates a 2-3% rise in comparable store sales for fiscal 2025. With a solid pre-tax margin, the company is poised for steady profitability, supported by improved merchandise margins. Also, management is on track with expansion efforts.
However, the company has been grappling with increased costs for a while now. Rising selling, general and administrative (SG&A) expenses are a concern for the company. Unfavorable foreign currency fluctuations might also act as a deterrent.
(You can read the full research report on TJX here >>>)
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +7.0 average gain per year. Amazingly, they soared with average gains of +44.9%, +48.4% and +55.2% per year.
Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.